Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

Incyte Corporation Call Center (ex-US) +800 00027423
eumedinfo@incyte.com


Incyte Corporation Call Center (US) 1.855.463.3463
medinfo@incyte.com


Study Location:

Find another location


Questions to ask
Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis
Back

A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis

Recruiting

Open to: ALL

Age: 6.0 - 17.0

Walsall Sheffield Glasgow Wirral London Nottingham

Medical Conditions

Dermatitis, Atopic
Dermatitis
Eczema

This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


The purpose of the study is to assess the efficacy and safety of ruxolitinib cream in children and adolescents (6 to \<18 Years Old) with moderate atopic dermatitis.

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Jun 2025 Jul 2026

INTERVENTIONAL

Intervention Type : DRUG
Intervention Description : The study cream will be applied topically as defined in the protocol for each period.

Intervention Arm Group : DC Period: Open Label - Ruxolitinib (1.5% Cream);Disease Control (DC) Period: Ruxolitinib (1.5% Cream);Open-label Extension (OLE) period: Ruxolitinib (1.5% Cream);Vehicle-controlled (VC) Period: Ruxolitinib (1.5% Cream);

Intervention Type : DRUG
Intervention Description : Matching vehicle cream will be applied topically as defined in the protocol for each period.

Intervention Arm Group : DC Period: Vehicle Cream;VC Period: Vehicle Cream;



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • Walsall Manor Hospital
    Walsall
    WS2 9PS
  • Sheffield Childrens Hospital
    Sheffield
    S10 2TH
  • West Glasgow Ambulatory Care Hospital
    Glasgow
    G3 8SJ
  • The Adam Practice
    Wirral
    CH49 5PE
  • St John'S Institute of Dermatology
    London
    SE1 7EH
  • University of Nottingham Health Service
    Nottingham
    NG7 2QW

Incyte Corporation Call Center (ex-US) +800 00027423
eumedinfo@incyte.com


Incyte Corporation Call Center (US) 1.855.463.3463
medinfo@incyte.com



The study is sponsored by Incyte Corporation



We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?
Read full details for Trial ID: NCT06832618
Last updated 02 July 2025

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.   

Back to the top